Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

Aged Angiogenesis Inhibitors/adverse effects Antibodies, Monoclonal/adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Carcinoma, Renal Cell/drug therapy,secondary Hemolytic-Uremic Syndrome/chemically induced Humans Hypertension/chemically induced Kidney Neoplasms/drug therapy,pathology Lung Neoplasms/drug therapy,secondary Male Thrombosis/chemically induced Vascular Endothelial Growth Factor A/antagonists & inhibitors

Angiogenesis Inhibitors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized VEGFA protein, human Vascular Endothelial Growth Factor A Bevacizumab